Dream to Reality: Sarepta's ELEVIDYS Dosing at the CureDuchenne Clinic

This August, time was running out for Hudson, a brave boy diagnosed with Duchenne muscular dystrophy just shy of his fifth birthday. His family, unfamiliar with the disease, had to navigate a world of uncertainty and fading hope swiftly.
Their determination met a glimmer of hope when the U.S. FDA approved Elevidys -a pioneering gene therapy by Sarepta Therapeutics for boys aged 4-5. With days to spare before Hudson turned six, making him ineligible for the treatment, he began his Elevidys journey at our flagship CureDuchenne Clinic.
That day, the dark cloud of Duchenne lifted just a bit.
Yet, Hudson's story isn't where this ends. Elevidys only reaches a small fraction of those with Duchenne. Our mission is broader and more ambitious.
Your support is crucial. Through strategic investments, like the one behind Elevidys, we aim to expand treatments for everyone affected by Duchenne, regardless of age. As this year ends, your contribution can accelerate these advancements, lighting the path towards more success stories.
Help us bring hope to every child, every family, and every individual battling Duchenne.
DONATE:
fundraise.givesmart.com/e/3qo...